NCHBL-005 and its metabolite indole-3-acetaldehyde alleviate psoriatic inflammation through modulation of the aryl hydrocarbon receptor-interleukin-1 beta-interleukin-17A axis, thereby restoring skin immune homeostasis. This study highlights postbiotic intervention in the aryl hydrocarbon receptor-interleukin-1 beta-interleukin-17A axis as a promising therapeutic strategy for psoriasis.

P1, N=50, Recruiting, Inimmune Corporation | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Aug 2024 --> Oct 2026

P1, N=9, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=399 --> 9 | Trial completion date: Sep 2029 --> Apr 2026 | Trial primary completion date: Sep 2028 --> Mar 2026

P1, N=51, Completed, UroGen Pharma Ltd. | Active, not recruiting --> Completed

We fabricated tumor-targeting liposome-chitosan-CPBA (LPCB) nanoparticles coloaded with doxorubicin (Dox), a chemotherapeutic agent, and resiquimod (R848), a toll-like receptor (TLR) 7/8 agonist that stimulates antitumor immunity...Flow cytometric analysis of tumor and spleen samples further showed robust activation of Natural Killer (NK) cells, CD4+ T cells, and CD8+ T cell effector functions. Combined results demonstrate that sialic acid targeting LPCBDR nanoparticles offers a promising drug delivery platform for bladder cancer therapy.

Our findings identify IL-27 signaling in keratinocytes as a pivotal regulator of skin inflammation in both psoriasis and AD. This highlights IL-27 as a promising therapeutic target for inflammatory skin diseases.

Moreover, compound 2 showed a potent therapeutic effect on the psoriasiform skin lesions induced by imiquimod in mice by inhibiting the expression of S100A9 and keratinocyte proliferation. As the pioneering examples of natural products demonstrate inhibitory action against S100A8/A9 complex, this discovery provides a series of compelling lead compounds with novel molecular scaffold for treating psoriasis.

Despite appropriate topical treatment with imiquimod, adjunctive cryotherapy, and herbal immunomodulatory agents, the lesions remained resistant to therapy. Consideration of genital examination and prophylactic HPV vaccination prior to initiating JAK inhibitor therapy may be warranted. Furthermore, in cases of treatment-resistant genital warts, reassessing the patient's systemic immune status and current immunosuppressive medications may lead to improved clinical outcomes.

In this work, we report on absorbable microspheres with excellent loading and controlled release of epirubicin and imiquimod, a toll-like receptor 7 agonist (EPI/IMQ@Asphere) for transarterial chemo-immuno-embolization (TACIE) in liver tumors. TACIE in orthotopic VX2 rabbit model reveals significant shrinkage of primary liver tumor and complete prevention of pulmonary metastasis, in which TACIE not only occludes tumor arteries and kills tumor cells but also amplifies tumoral CD8+/CD4+ T cell infiltration. Overall, TACIE based on EPI/IMQ@Asphere offers a highly appealing therapeutic strategy for advanced liver cancers.

P2, N=16, Completed, Melanoma Institute Australia | Recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2025 | Trial primary completion date: Jun 2026 --> Mar 2025

In conclusion, this study provides the first preclinical evidence that HMC, particularly in combination with MTX, ameliorates IMQ-induced psoriasis via modulation of inflammatory cytokines, oxidative stress, and histopathological damage. These findings suggest its potential as a therapeutic candidate that warrants further preclinical and clinical investigation in plaque-type psoriasis.

Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition.